abstract
- Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.
In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- June 2021
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Benzhydryl Compounds (MeSH)
- Glucosides (MeSH)
- Heart Failure (MeSH)
- Humans (MeSH)
- Renal Insufficiency, Chronic (MeSH)
- Stroke Volume (MeSH)
published in
- ACP journal club Journal